Bard Financial Services Inc. Raises Position in GSK PLC Sponsored ADR $GSK

Key Points

• Bard Financial Services Inc. increased its stake in GSK PLC by 10.2%, now owning 134,745 shares valued at approximately $5.17 million.
• GSK's recent quarterly earnings showed an EPS of $1.23, surpassing estimates, and a revenue of $10.64 billion, indicative of a 1.3% year-over-year growth.
• The company has announced a quarterly dividend of $0.4206, which translates to an annualized dividend yield of 4.1%.

Bard Financial Services Inc. boosted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 10.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 134,745 shares of the pharmaceutical company's stock after purchasing an additional 12,500 shares during the period. Bard Financial Services Inc.'s holdings in GSK were worth $5,174,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of GSK. Brighton Jones LLC purchased a new position in shares of GSK during the fourth quarter worth about $528,000. Quantinno Capital Management LP grew its stake in shares of GSK by 7.0% in the 4th quarter. Quantinno Capital Management LP now owns 106,753 shares of the pharmaceutical company's stock valued at $3,610,000 after purchasing an additional 6,948 shares during the last quarter. Tidal Investments LLC increased its holdings in shares of GSK by 6.2% in the fourth quarter. Tidal Investments LLC now owns 31,015 shares of the pharmaceutical company's stock valued at $1,049,000 after purchasing an additional 1,823 shares during the period. Two Sigma Investments LP raised its stake in shares of GSK by 602.5% during the fourth quarter. Two Sigma Investments LP now owns 574,754 shares of the pharmaceutical company's stock worth $19,438,000 after purchasing an additional 492,934 shares during the last quarter. Finally, Visionary Wealth Advisors lifted its holdings in shares of GSK by 5.6% during the fourth quarter. Visionary Wealth Advisors now owns 193,378 shares of the pharmaceutical company's stock worth $6,540,000 after purchasing an additional 10,178 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

Shares of NYSE:GSK traded up $0.33 on Friday, hitting $40.63. The company had a trading volume of 1,655,184 shares, compared to its average volume of 5,006,294. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $42.63. The business has a 50 day moving average of $38.85 and a 200 day moving average of $38.53. The company has a market cap of $82.74 billion, a PE ratio of 18.79, a PEG ratio of 2.01 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business's revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.1%. GSK's dividend payout ratio is presently 77.78%.

Analysts Set New Price Targets

GSK has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 5th. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.